Overview

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    pH: 7.30
    Preservative: 0.02% Sodium azide
    Constituents: 0.05% Tris, 0.5% BSA
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Purification notes
    Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab2230 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 51 kDa.Can be blocked with Human BLNK peptide (ab22871).

Approx 70kDa band seen in Daudi lysate.

Target

  • Function
    Functions as a central linker protein that bridges kinases associated with the B-cell receptor (BCR) with a multitude of signaling pathways, regulating biological outcomes of B-cell function and development. Plays a role in the activation of ERK/EPHB2, MAP kinase p38 and JNK. Modulates AP1 activation. Important for the activation of NF-kappa-B and NFAT. Plays an important role in BCR-mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is required for trafficking of the BCR to late endosomes. However, does not seem to be required for pre-BCR-mediated activation of MAP kinase and phosphatidyl-inositol 3 (PI3) kinase signaling. May be required for the RAC1-JNK pathway. Plays a critical role in orchestrating the pro-B cell to pre-B cell transition (By similarity). Plays an important role in BCR-induced B-cell apoptosis.
  • Tissue specificity
    Expressed in B-cell lineage and fibroblast cell lines (at protein level). Highest levels of expression in the spleen, with lower levels in the liver, kidney, pancreas, small intestines and colon.
  • Involvement in disease
    Defects in BLNK are the cause of agammaglobulinemia type 4 (AGM4) [MIM:613502]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.
  • Sequence similarities
    Contains 1 SH2 domain.
  • Post-translational
    modifications
    Following BCR activation, phosphorylated on tyrosine residues by SYK and LYN. When phosphorylated, serves as a scaffold to assemble downstream targets of antigen activation, including PLCG1, VAV1, GRB2 and NCK1. Phosphorylation of Tyr-84, Tyr-178 and Tyr-189 facilitates PLCG1 binding. Phosphorylation of Tyr-96 facilitates BTK binding. Phosphorylation of Tyr-72 facilitates VAV1 and NCK1 binding. Phosphorylation is required for both Ca(2+) and MAPK signaling pathways.
  • Cellular localization
    Cytoplasm. Cell membrane. BCR activation results in the translocation to membrane fraction.
  • Information by UniProt
  • Database links
  • Alternative names
    • AGM4 antibody
    • B cell adapter containing SH2 domain protein antibody
    • B cell adapter containing Src homology 2 domain protein antibody
    • B cell adaptor containing SH2 domain antibody
    • B cell linker antibody
    • B cell linker protein antibody
    • B cell-specific adaptor protein antibody
    • B-cell activation antibody
    • B-cell adapter containing a SH2 domain protein antibody
    • B-cell adapter containing a Src homology 2 domain protein antibody
    • B-cell linker protein antibody
    • BASH antibody
    • Bca antibody
    • BLNK antibody
    • BLNK s antibody
    • BLNK_HUMAN antibody
    • Cytoplasmic adapter protein antibody
    • Ly 57 antibody
    • Ly57 antibody
    • Lymphocyte antigen 57 antibody
    • Lyw 57 antibody
    • Lyw57 antibody
    • MGC111051 antibody
    • SH2 domain-containing leukocyte protein, 65-KD antibody
    • SLP 65 antibody
    • SLP-65 antibody
    • SLP65 antibody
    • Src homology [SH2] domain-containing leukocyte protein of 65 kD antibody
    • Src homology 2 domain containing leukocyte protein of 65 kDa antibody
    • Src homology 2 domain-containing leukocyte protein of 65 kDa antibody
    see all

Images

  • Anti-BLNK antibody (ab2230) at 4 µg/ml + Cell lysate prepared from human Daudi cells at 35 µg

    Developed using the ECL technique.

    Predicted band size: 51 kDa
    Observed band size: 70 kDa (why is the actual band size different from the predicted?)



    Ab2230 staining (4µg/ml) of Daudi lysate (RIPA buffer, 30µg total protein per lane).  Primary incubated for 1 hour.  Detected by western blot using chemiluminescence Primary incubated for 1 hour.
  • All lanes : Anti-BLNK antibody (ab2230) at 1 µg/ml

    Lane 1 : Cell lysate prepared from HEK293 mock transfected cells
    Lane 2 : Cell lysate prepared from HEK293 overexpressing BLNK

    Predicted band size: 51 kDa
    Observed band size: 50 kDa (why is the actual band size different from the predicted?)

References

ab2230 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab2230.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up